Extra scrutiny for industry funded trials

BMJ 2005; 331 doi: 10.1136/bmj.331.7529.1350 (Published 8 December 2005)
Cite this as: BMJ 2005;331:1350

This article has a correction

Please see: Extra scrutiny for industry funded trials

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Kenneth J Rothman, vice president, epidemiology research,
  2. Stephen Evans, professor of pharmacoepidemiology (stephen.evans@lshtm.ac.uk)
  1. RTI Health Solutions, RTI International, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA
  2. Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London WC1 7HT

    JAMA's demand for an additional hurdle is unfair—and absurd

    Suppose that a biomedical journal invoked a new policy requiring that all authors based in western Europe or North America would receive ordinary peer review, but authors from other countries would receive a peer review with additional hurdles. This policy may seem unfair, but suppose the journal claimed that research has shown that there is a greater prevalence of fraud, bias, and sloppy work among papers coming from these other countries.

    If these events actually transpired, we hope that other biomedical journals would rapidly point out that adopting such a policy would be unfair to authors from non-western countries, even if the premises for it were valid. Indeed, we hope that other editors would decide that it would be unethical to create any hierarchical system for submissions of papers to a biomedical journal. Peer review ought to rest …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL